Business
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference
SARASOTA, Fla., Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\" or the \"Company\"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, announced today that Steve Shum, CEO, will be participating in a Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also be conducting one-on-one meetings with investors.\n\n \n \n \n \n \n \n\n \nPanel PresentationMr. Shum will be participating in a panel titled, \"Fertility Frontiers: Leading Edge Technologies Addressing the Fertility Market.\" This panel, also to be conducted virtually, will be held on Tuesday, October 17, 2023, at 12:00 pm ET. To access the panel, please visit: https://wsw.com/webcast/lytham9/panel3/2274168.\n1x1 MeetingsManagement will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at https://www.lythampartners.com/fall2023invreg/. \nAbout INVO Bioscience\nWe are a healthcare services fertility company dedicated to expanding the assisted reproductive technology (\"ART\") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated \"INVO Centers\" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization (\"IVF\") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as \"IVC\", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a signifi...